Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash

Royalty Pharma, an investor in royalty streams from pharmaceuticals, raised its offer to buy Elan Corp. by 12 percent to $6.4 billion after the Irish drugmaker made acquisitions to boost revenue and resist the bid.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.